 The study is a two-arm randomised controlled non-inferiority and cost-effectiveness trial. The trial will be conducted in routine mental health care in Poland, and is a part of the bigger project funded by European Commission Grant Agreement No: 603098. A total of 150 patients with MDD will be assigned to one of two conditions: 1 blended CBT, 2 TAU. Respondents in both conditions will be followed until 12 months after baseline measures will be taken at baseline, 3 months, 6 months and 12 months. 